Shares of Vera Therapeutics Inc. plummeted over 9% on Monday after the late-stage biotech company announced pricing for a $300 million public offering of its Class A common stock.
Vera said it plans to sell 7.1 million shares at $42 apiece, with underwriters having a 30-day option to purchase an additional 1.1 million shares. The offering is expected to close on October 31st.
The sizable equity raise will dilute existing shareholders but provides Vera with cash to fund ongoing development of its pipeline candidates, including atacicept for autoimmune diseases like IgA nephropathy and lupus nephritis, as well as MAU868 for preventing BK virus infection after kidney transplants.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。